MedCity News January 8, 2024
Medical device giant Boston Scientific added to its string of recent acquisitions by announcing its plan to buy Axonics, a maker of neurostimulation devices that treat urinary and bowel dysfunction, for $3.7 billion. Experts agree that this deal will make a profitable impact on Boston Scientific’s urology business.
Medical device giant Boston Scientific announced a $3.7 billion deal on Monday to augment its urology portfolio. The company is acquiring Axonics, a maker of neurostimulation devices that treat urinary and bowel dysfunction, for $71 in cash per share.
The deal, announced at this year’s J.P. Morgan Healthcare Conference in San Francisco, is expected to close in the first half of 2024. Experts agree that the acquisition of Axonics’ device portfolio will...
Today's Sponsors
Today's Sponsor